We recently published an article titled 11 High-Growth Micro-Cap Stocks to Buy.

On January 7, Stifel analyst Rick Wise reduced the price objective on Outset Medical, Inc. (NASDAQ:ABOUT) to $8 from $14, maintaining a buy rating on the stock. The adjustment reflects near-term pressures on MedTech after 2025, although the company remains constructive on the overall sector for 2026.

Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In the third quarter of 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Sales of Tablo consoles increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.

Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of the largest and most expensive segments of healthcare, through innovative technology, research and American manufacturing operations.

While we recognize the potential of OM as an investment, we believe that certain AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 8 Emerging streaming companies and services i 9 High Growth Canadian Stocks to Buy

Disclosure: no.